Journal Home > Volume 1 , Issue 1
Background

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019 and has led to a global coronavirus disease 2019 (COVID-19) pandemic. Currently, incomplete understanding of how SARS-CoV-2 arrogates the host cell to establish its life cycle has led to slow progress in the development of effective drugs.

Results

In this study, we found that SARS-CoV-2 hijacks the host protein EWSR1 (Ewing Sarcoma breakpoint region 1/EWS RNA binding protein 1) to promote the activity of its helicase NSP13 to facilitate viral propagation. NSP13 is highly conserved among coronaviruses and is crucial for virus replication, providing chemical energy to unwind viral RNA replication intermediates. Treatment with different SARS-CoV-2 NSP13 inhibitors in multiple cell lines infected with SARS-CoV-2 effectively suppressed SARS-CoV-2 infection. Using affinity-purification mass spectrometry, the RNA binding protein EWSR1 was then identified as a potent host factor that physically associated with NSP13. Furthermore, silencing EWSR1 dramatically reduced virus replication at both viral RNA and protein levels. Mechanistically, EWSR1 was found to bind to the NTPase domain of NSP13 and potentially enhance its dsRNA unwinding ability.

Conclusions

Our results pinpoint EWSR1 as a novel host factor for NSP13 that could potentially be used for drug repurposing as a therapeutic target for COVID-19.

File
imj-1-1-7-esm1.docx (22.6 KB)
imj-1-1-7-esm2.docx (159 KB)
imj-1-1-7-esm3.docx (593.9 KB)
Publication history
Copyright
Acknowledgements
Rights and permissions

Publication history

Received: 25 October 2021
Revised: 11 December 2021
Accepted: 29 December 2021
Published: 24 February 2022
Issue date: March 2022

Copyright

© The Author(s) 2022. Published by Elsevier Ltd on behalf of Tsinghua University Press.

Acknowledgements

Acknowledgement

We thank Prof. Pei-hui Wang from Shandong University for kindly providing us with the NSP13 plasmids.

Rights and permissions

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Return